[go: up one dir, main page]

LUC00015I2 - - Google Patents

Info

Publication number
LUC00015I2
LUC00015I2 LU00015C LUC00015C LUC00015I2 LU C00015 I2 LUC00015 I2 LU C00015I2 LU 00015 C LU00015 C LU 00015C LU C00015 C LUC00015 C LU C00015C LU C00015 I2 LUC00015 I2 LU C00015I2
Authority
LU
Luxembourg
Application number
LU00015C
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41100519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00015(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of LUC00015I1 publication Critical patent/LUC00015I1/fr
Publication of LUC00015I2 publication Critical patent/LUC00015I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
LU00015C 2008-05-21 2017-04-12 LUC00015I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5512008P 2008-05-21 2008-05-21
EP09751584.5A EP2296686B2 (fr) 2008-05-21 2009-05-21 Desmopressine orodispersible augmentant la période initiale de sommeil non perturbé par la nycturie

Publications (2)

Publication Number Publication Date
LUC00015I1 LUC00015I1 (fr) 2017-04-19
LUC00015I2 true LUC00015I2 (fr) 2017-06-19

Family

ID=41100519

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00015C LUC00015I2 (fr) 2008-05-21 2017-04-12

Country Status (16)

Country Link
US (2) US9974826B2 (fr)
EP (5) EP3225250B1 (fr)
JP (5) JP5767103B2 (fr)
CA (1) CA2724653A1 (fr)
DK (5) DK3085381T3 (fr)
ES (5) ES2710454T3 (fr)
HR (4) HRP20161066T1 (fr)
HU (5) HUE030409T2 (fr)
LT (5) LT3085381T (fr)
LU (1) LUC00015I2 (fr)
NO (3) NO2296686T3 (fr)
PL (5) PL2296686T5 (fr)
PT (5) PT2296686E (fr)
SI (4) SI3225250T1 (fr)
TR (2) TR201819189T4 (fr)
WO (1) WO2009143356A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
SI3225250T1 (sl) * 2008-05-21 2019-11-29 Ferring Bv Orodisperzibilen dezmopresin za podaljšanje začetnega obdobja spanja, ki ga ne moti nokturija
WO2015063602A1 (fr) * 2013-10-29 2015-05-07 Ferring B.V. Desmopressine et glycémie
EP3868215A4 (fr) * 2018-10-16 2022-07-27 Nippon Chemiphar Co., Ltd. Agent améliorant la qualité du sommeil
JP7482033B2 (ja) * 2018-10-17 2024-05-13 日本ケミファ株式会社 夜間多尿の治療又は予防剤
AU2021257176A1 (en) * 2020-04-14 2022-11-10 Nippon Chemiphar Co., Ltd. Sleep quality improver
WO2022103635A1 (fr) 2020-11-16 2022-05-19 Orcosa Inc. Plate-forme d'infusion rapide et compositions pour un traitement thérapeutique chez les humains
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4285858A (en) 1979-10-30 1981-08-25 Mt. Sinai School Of Medicine Of The City University Of N.Y. Vasopressin analogs
US4263283A (en) 1980-05-16 1981-04-21 Ferring Pharmaceuticals, Inc. Method for prophylaxis and/or treatment of sickle cell disease
GB2111423B (en) 1981-12-02 1985-06-26 Wyeth John & Brother Ltd Making quick-dissolving pills
ATE24964T1 (de) 1981-12-11 1987-01-15 Wyeth John & Brother Ltd Verfahren zur herstellung von festen formgegenstaenden.
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
SE8306367L (sv) 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4878892A (en) 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
DK365389D0 (da) 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
TW279133B (fr) 1990-12-13 1996-06-21 Elan Med Tech
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
SE9101022D0 (sv) 1991-01-09 1991-04-08 Paal Svedman Medicinsk suganordning
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
CA2070061C (fr) 1991-06-07 2004-02-10 Shigeyuki Takama Composition pharmaceutique renfermant des polypeptides physiologiquement actives
CA2103163C (fr) 1991-08-26 1998-10-20 Mou-Ying Fu Lu Compositions et methodes pour l'administratiion sublinguale ou buccale d'agents therapeutiques
NZ246091A (en) 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
US5298256A (en) 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CA2090738C (fr) 1993-02-24 1996-05-21 Hema-Quebec Utilisation du paf
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US5434121A (en) * 1993-03-25 1995-07-18 Mitsui Toatsu Chemicals, Incorporated Variety of Drechslera monoceras, weed control compositions containing the same as an effective ingredient and weed control methods using the same
SE501677C2 (sv) 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
US5674850A (en) 1993-12-23 1997-10-07 Ferring Ab High purity desmopressin produced in large single batches
ATE193892T1 (de) 1993-06-29 2000-06-15 Ferring Bv Synthese zyklischer peptide
US5500413A (en) 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
US5482931A (en) 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5985835A (en) 1993-12-23 1999-11-16 Ferring B.V. Desmopressin for nocturia, incontinence and enuresis
HK1000906A1 (en) 1993-06-29 2002-03-08 Ferring B.V. Compositions for nasal administration of desmopressin
DE69434626D1 (de) 1993-11-17 2006-04-20 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
DE19518932C2 (de) 1994-05-23 1999-03-18 Samsung Electro Mech Vorrichtung zur Perforation der Haut für die Vorbereitung einer transdermalen Medikation
DE4424800A1 (de) * 1994-07-14 1996-01-18 Philips Patentverwaltung Schaltungsanordnung zum Liefern von Speisespannungen
SE518619C2 (sv) 1994-12-09 2002-10-29 Gs Dev Ab Komposition för reglerad frisättning innehållande monokaproin
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US5843016A (en) 1996-03-18 1998-12-01 Physion S.R.L. Electromotive drug administration for treatment of acute urinary outflow obstruction
TW411277B (en) 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
CA2253549C (fr) 1996-06-18 2005-10-25 Alza Corporation Dispositif d'amelioration d'apport ou d'echantillonnage d'agents transdermiques
US5763398A (en) 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
FR2758195B1 (fr) 1997-01-09 1999-02-26 Sgs Thomson Microelectronics Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
US5932745A (en) 1997-07-30 1999-08-03 American Home Products Corporation Process for converting propargylic amine-N-oxides to enaminones
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US6090803A (en) 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
GB9827292D0 (en) 1998-12-12 1999-02-03 Univ Strathclyde Freeze drying
US6406455B1 (en) 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
US20060025387A1 (en) 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
US6620807B1 (en) 1999-02-04 2003-09-16 Wyeth Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
US6344451B1 (en) 1999-02-04 2002-02-05 American Home Products Pyrrolobenzodiazepine carboxyamide vasopressin agonists
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
US6235900B1 (en) 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
ATE283708T1 (de) 1999-02-15 2004-12-15 Sumitomo Pharma Im mundraum schnellzerfallende tabletten
ATE342097T1 (de) 1999-02-18 2006-11-15 Biovalve Technologies Inc Elektroaktive pore
AR014640A1 (es) 1999-02-23 2001-03-28 Univ Nac Quilmes UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB2355454A (en) 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
ATE501751T1 (de) 2000-01-07 2011-04-15 Valeritas Inc Injektionsvorrichtung
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
WO2002094368A1 (fr) 2000-10-26 2002-11-28 Alza Corporation Dispositifs d'administration de medicament transdermique avec des microprotrusions enrobees
US7931614B2 (en) 2000-11-30 2011-04-26 Valeritas, Inc. Injection systems
US6939324B2 (en) 2000-11-30 2005-09-06 Biovalve Technologies, Inc. Fluid delivery and measurement systems and methods
US9302903B2 (en) 2000-12-14 2016-04-05 Georgia Tech Research Corporation Microneedle devices and production thereof
US7027478B2 (en) 2000-12-21 2006-04-11 Biovalve Technologies, Inc. Microneedle array systems
ES2270746T3 (es) 2001-03-16 2007-12-01 Alza Corporation Parche transdermico para administrar fentanilo.
EP1381608B1 (fr) 2001-04-12 2007-10-10 Wyeth Cyclohexylphenyles ayant une activite d'agonistes de la vasopressine
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6903091B2 (en) 2001-04-12 2005-06-07 Wyeth Biphenyl vasopressin agonists
US7615234B2 (en) 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
ES2314092T3 (es) 2001-09-13 2009-03-16 Kissei Pharmaceutical Co., Ltd. Cristales de un derivado de hidroxinorefredina.
US6723077B2 (en) 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
JP4075064B2 (ja) 2001-11-16 2008-04-16 アステラス製薬株式会社 ４，４−ジフルオロ−１，２，３，４−テトラヒドロ−５ｈ−１−ベンゾアゼピン誘導体又はその塩
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
CA2484724C (fr) * 2002-05-07 2007-01-16 Ferring B.V. Formulations pharmaceutiques
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
GB2421689B (en) 2002-08-05 2007-03-07 Caretek Medical Ltd Drug delivery system
US20040115167A1 (en) 2002-09-30 2004-06-17 Michel Cormier Drug delivery device and method having coated microprojections incorporating vasoconstrictors
KR101060629B1 (ko) 2002-10-09 2011-08-31 도레이 카부시키가이샤 빈뇨 혹은 요실금의 치료 또는 예방제 및 함질소 환상치환기를 갖는 몰피난 유도체
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
EP1428526A1 (fr) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Composition pour dissolution rapid d'un composè lipophile
DE10259934B3 (de) 2002-12-20 2004-10-14 H.C. Starck Gmbh Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1619185B1 (fr) 2003-04-28 2011-06-15 Astellas Pharma Inc. Derive de 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine ou sel de celui-ci
US20060193825A1 (en) 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
DE602004008278T2 (de) 2003-06-30 2008-02-14 Alza Corp., Mountain View Transdermale Abgabevorrichtung zur Abgabe eines biologisch aktiven Mittels mit hydrophober und hydrophiler Beschichtung
ES2243840T3 (es) 2003-07-25 2005-12-01 Ferring B.V. Composicion farmaceutica de desmopresina como forma farmaceutica solida de dosificacion y metodo para la fabricacion de la misma.
CN1826099B (zh) 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
US6930932B2 (en) 2003-08-27 2005-08-16 Hewlett-Packard Development Company, L.P. Data signal reception latch control using clock aligned relative to strobe signal
EP1675539A4 (fr) 2003-10-24 2007-09-12 Alza Corp Procede et systeme de pretraitement permettant d'ameliorer l'administration transdermique de medicaments
EP1680057A4 (fr) 2003-10-24 2007-10-31 Alza Corp Dispositif et procede d'amelioration de l'administration transdermique de medicament
EP1680154B1 (fr) 2003-10-31 2012-01-04 ALZA Corporation Applicateur a actionnement automatique pour reseau de micro-protuberances
EP2322198A2 (fr) † 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
DE60305043T2 (de) 2003-11-13 2006-11-30 Ferring B.V. Blisterverpackung und feste Dosierungsform enthaltend Desmopressin
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
SI1550439T1 (sl) 2003-12-29 2006-08-31 Ferring Bv Postopek za pripravo trdne dozirne oblike dezmopresina
WO2005069758A2 (fr) 2004-01-09 2005-08-04 Alza Corporation Procede et systeme d'administration d'agent par voie transdermique assiste par frequence
WO2006029411A2 (fr) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Melanges de polypeptides, compositions les contenant et leurs procedes de preparation et d'utilisation
US7097776B2 (en) 2004-10-22 2006-08-29 Hewlett-Packard Development Company, L.P. Method of fabricating microneedles
US20060093658A1 (en) 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
CN100339081C (zh) 2004-11-10 2007-09-26 范敏华 一种氯雷他定口腔崩解片剂的制备方法
US7180274B2 (en) 2004-12-10 2007-02-20 Aimtron Technology Corp. Switching voltage regulator operating without a discontinuous mode
CA2605580A1 (fr) 2005-04-22 2006-11-02 Wyeth Derives benzodioxanne et benzodioxolanne et leurs utilisations
PE20070093A1 (es) 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
AU2006239922A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
US7856263B2 (en) 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
TW200716595A (en) 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
WO2006116169A2 (fr) 2005-04-24 2006-11-02 Wyeth Methodes permettant de moduler la fonction vesicale
CA2612005C (fr) 2005-06-17 2013-10-29 Georgia Tech Research Corporation Microstructures revetues et procede de fabrication de celles-ci
US20080195035A1 (en) 2005-06-24 2008-08-14 Frederickson Franklyn L Collapsible Patch and Method of Application
WO2007083323A2 (fr) 2006-01-23 2007-07-26 Panacea Biotec Limited. Administration orale de desmopressine et de ses sels
WO2007098945A2 (fr) 2006-03-02 2007-09-07 Ferring International Center S.A. Composition comprenant de la desmopressine
WO2007127976A2 (fr) 2006-05-01 2007-11-08 Georgia Tech Research Corporation Procédé de moulage basé sur des particules
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
SI3225250T1 (sl) * 2008-05-21 2019-11-29 Ferring Bv Orodisperzibilen dezmopresin za podaljšanje začetnega obdobja spanja, ki ga ne moti nokturija

Also Published As

Publication number Publication date
SI3085381T1 (en) 2018-06-29
HRP20190114T1 (hr) 2019-03-08
JP5767103B2 (ja) 2015-08-19
HUE030409T2 (en) 2017-05-29
PT2296686E (pt) 2014-05-23
ES2756706T3 (es) 2020-04-27
HRP20180774T1 (hr) 2018-08-10
DK3085381T3 (en) 2018-05-28
JP2019123739A (ja) 2019-07-25
JP2011520980A (ja) 2011-07-21
JP6506821B2 (ja) 2019-04-24
WO2009143356A1 (fr) 2009-11-26
ES2710454T3 (es) 2019-04-25
EP3225249B1 (fr) 2018-11-07
HUE041370T2 (hu) 2019-05-28
LUC00015I1 (fr) 2017-04-19
EP3085381B1 (fr) 2018-04-18
NO3085381T3 (fr) 2018-09-15
ES2596435T3 (es) 2017-01-09
TR201819189T4 (tr) 2019-01-21
LT2712622T (lt) 2016-09-26
SI3225249T1 (sl) 2019-02-28
SI2712622T1 (sl) 2016-10-28
PL2296686T3 (pl) 2014-07-31
US20090291880A1 (en) 2009-11-26
NO2296686T3 (fr) 2014-07-12
PL3225249T3 (pl) 2019-05-31
US20180250357A1 (en) 2018-09-06
EP3225250A1 (fr) 2017-10-04
JP6001121B2 (ja) 2016-10-05
ES2462465T3 (es) 2014-05-22
JP2015120761A (ja) 2015-07-02
US9974826B2 (en) 2018-05-22
HUE046050T2 (hu) 2020-01-28
JP2016196514A (ja) 2016-11-24
LT3225250T (lt) 2019-11-11
PL2712622T3 (pl) 2017-01-31
NO2019021I1 (no) 2019-04-30
LTC2712622I2 (lt) 2020-02-10
JP2018035198A (ja) 2018-03-08
HRP20161066T1 (hr) 2016-10-21
JP6258424B2 (ja) 2018-01-10
LT3085381T (lt) 2018-06-11
LT3225249T (lt) 2019-01-10
PT3085381T (pt) 2018-05-18
PL3225250T3 (pl) 2020-02-28
CA2724653A1 (fr) 2009-11-26
EP3085381A1 (fr) 2016-10-26
DK2296686T4 (en) 2018-01-02
TR201807224T4 (tr) 2018-06-21
EP3225250B1 (fr) 2019-08-21
ES2462465T5 (es) 2018-02-28
HUE039013T4 (hu) 2019-08-28
EP3225249A1 (fr) 2017-10-04
JP6836618B2 (ja) 2021-03-03
HUE039013T2 (hu) 2018-12-28
SI3225250T1 (sl) 2019-11-29
DK3225250T3 (da) 2019-11-04
PL3085381T3 (pl) 2018-09-28
EP2296686B2 (fr) 2017-11-01
PT3225250T (pt) 2019-10-15
PL2296686T5 (pl) 2018-06-29
DK2712622T3 (en) 2016-09-12
PT2712622T (pt) 2016-10-13
EP2296686A1 (fr) 2011-03-23
EP2296686B1 (fr) 2014-02-12
DK3225249T3 (en) 2019-02-25
LTPA2017001I1 (lt) 2017-02-10
PT3225249T (pt) 2019-01-17
ES2677548T3 (es) 2018-08-03
EP2712622A1 (fr) 2014-04-02
EP2712622B1 (fr) 2016-07-13
DK2296686T3 (da) 2014-05-12
HUS1900024I1 (hu) 2019-05-28
HRP20191854T1 (hr) 2019-12-27

Similar Documents

Publication Publication Date Title
BRPI0917573A2 (fr)
BRPI0918697A2 (fr)
BRPI0917525A2 (fr)
BRPI0920750A2 (fr)
BRPI0919470A2 (fr)
BRPI0922455A2 (fr)
BRPI0923734A2 (fr)
BRPI0917618A8 (fr)
BRPI0912727A2 (fr)
BRPI0922669A2 (fr)
BRPI0914750A2 (fr)
BRPI0919811A2 (fr)
BRPI0915616A2 (fr)
BRPI0920914A2 (fr)
BRPI0922550A2 (fr)
BRPI0916284A2 (fr)
BRPI0914852A2 (fr)
BRPI0913605A2 (fr)
LUC00015I2 (fr)
CH2352018H2 (fr)
BRPI0914820A2 (fr)
BRPI0919477A2 (fr)
BRPI0923127A (fr)
BRPI0923137A2 (fr)
CL47313B1 (fr)